A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer
Status:
Recruiting
Trial end date:
2028-02-01
Target enrollment:
Participant gender:
Summary
This Phase 3, multinational, single-arm, multicenter study will evaluate the efficacy and
safety of UGN-102 as primary chemoablative therapy in patients with low grade intermediate
risk non-muscle-invasive bladder cancer (LG IR NMIBC).